At the Crest of Innovation | Professors Jian Zhang and Songqing Ye Discuss the Frontiers of ADC Therapy in Breast Cancer

At the Crest of Innovation | Professors Jian Zhang and Songqing Ye Discuss the Frontiers of ADC Therapy in Breast Cancer

Antibody–drug conjugates (ADCs) are reshaping the treatment landscape of breast cancer at an unprecedented pace. From HER2 to Trop-2, and from late-line metastatic settings to early-stage neoadjuvant therapy, ADC indications continue to expand while efficacy breakthroughs accumulate. Oncology Frontier invited Professor Jian Zhang from Fudan University Shanghai Cancer Center and Professor Songqing Ye from Fujian Provincial Hospital to engage in an in-depth discussion on the evolution of ADCs, recent clinical advances, toxicity management, and future trends. Drawing on cutting-edge clinical data and real-world experience, the two experts offer valuable insights into efficacy optimization, toxicity management, frontline integration, combination strategies, and drug diversification.
The 8th Tongji Breast Cancer Forum | Professor Huihua Xiong: Integrating Top Academic Expertise to Advance Regional Breast Cancer Care

The 8th Tongji Breast Cancer Forum | Professor Huihua Xiong: Integrating Top Academic Expertise to Advance Regional Breast Cancer Care

With the arrival of spring, the 8th Tongji Breast Cancer Forum was successfully convened, focusing on key topics including clinical needs, cutting-edge advances, grassroots implementation, and the development of young physicians. The meeting not only built a bridge for in-depth dialogue between leading experts and frontline clinicians, but also offered fresh perspectives on integrating clinical practice with the latest scientific progress.
CSCO BC Preview | Professor Zefei Jiang: A Decade of Progress and a New Beginning—Join Us at the 2026 National Breast Cancer Conference

CSCO BC Preview | Professor Zefei Jiang: A Decade of Progress and a New Beginning—Join Us at the 2026 National Breast Cancer Conference

From April 10 to 12, 2026, the National Breast Cancer Conference will be held in Beijing. Marking the 10th anniversary of the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC), this annual flagship meeting will once again bring together leading experts from China and around the world to share cutting-edge research, interpret the latest guidelines and consensus statements, and exchange clinical experience—driving the high-quality development of breast cancer care in China. On the eve of the conference, Oncology Frontier invited Professor Zefei Jiang, Conference Chair and President-Elect of CSCO, to provide insights into the past decade of CSCO BC, the highlights of this year’s meeting, and key updates in the 2026 guidelines. We look forward to welcoming you in Beijing.
Beijing · April 24–25 | 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (AOT 2026) to Convene

Beijing · April 24–25 | 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (AOT 2026) to Convene

In order to comprehensively advance public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become pivotal forces in overcoming critical health challenges. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (Art of Transplant: Beijing Hematopoietic Stem Cell Transplantation Symposium, AOT 2026), hosted by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care, and organized by the National Clinical Research Center for Hematologic Diseases and the Institute of Hematology at Peking University, will be grandly held in Beijing on April 24–25, 2026.
Voice of China at EBMT 2026 | Professor Erlie Jiang / Dr. Xiaoyu Zhang: Exploring the Role of Third-Generation TKIs in Transplantation for Blast-Phase CML

Voice of China at EBMT 2026 | Professor Erlie Jiang / Dr. Xiaoyu Zhang: Exploring the Role of Third-Generation TKIs in Transplantation for Blast-Phase CML

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential academic events in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
Professor Haixia Fu: Applications and Advances of TPO Receptor Agonists and ATRA in the Treatment of ITP

Professor Haixia Fu: Applications and Advances of TPO Receptor Agonists and ATRA in the Treatment of ITP

From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis, hosted by the Hematologic Immunology Branch of the Chinese Society of Immunology, together with the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology, was successfully held in Beijing. The meeting brought together leading international and domestic experts, clinicians, and industry leaders to explore cutting-edge developments in thrombosis and hemostasis, hematologic malignancies, and immunology, while advancing academic exchange and innovation in the field.
Professor Heyu Ni: Interactions Between Platelets and the Immune System and Their Significance in Immune-Mediated Thrombocytopenia

Professor Heyu Ni: Interactions Between Platelets and the Immune System and Their Significance in Immune-Mediated Thrombocytopenia

From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis and the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology was successfully held in Beijing. The event brought together leading scholars, clinicians, and industry experts from around the world to exchange insights on cutting-edge developments in thrombosis and hemostasis, hematologic malignancies, and immunology, while shaping the future direction of the field.
Expert Interview | Prof. Shilpa Gupta Decodes Urothelial Carcinoma In-Depth: China’s Strength, Global Collaboration and Future Breakthroughs in the ADC Era

Expert Interview | Prof. Shilpa Gupta Decodes Urothelial Carcinoma In-Depth: China’s Strength, Global Collaboration and Future Breakthroughs in the ADC Era

In recent years, the rapid advancement of antibody-drug conjugates (ADCs) has completely reshaped the treatment paradigm across the entire disease course of urothelial carcinoma. Meanwhile, Chinese investigators and domestically developed innovative agents have gained ever-increasing influence in the global oncology landscape. Recently, we had the exclusive opportunity to interview Prof. Shilpa Gupta, a world-leading expert in urothelial carcinoma, Leading Principal Investigator of multiple pivotal international multicenter clinical trials from Cleveland Clinic. We conducted an in-depth, professional exchange with Prof. Gupta on core topics including the global positioning of China's clinical research in urological oncology, optimized pathways for cross-border research collaboration, the paradigm shift in diagnosis and treatment driven by ADCs, and the future disruptive breakthrough directions in the field. The following is the edited content of this interview.